DDInter1197 DDInter1376
Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition to gastroesophageal reflux disease (GERD). It can also be used to prevent nausea or vomiting associated with chemotherapy or certain surgical or diagnostic procedures. One unique property of this drug is that it does not increase gastric acid secretion. It is available in the oral tablet form or in solution, and can also be administered through the intravenous route. Metoclopramide was initially approved by the FDA in 1980.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Metoclopramide {u} (Compound) resembles {v} (Compound) Cinchocaine
Metoclopramide {u} (Compound) resembles {v} (Compound) Procaine
Metoclopramide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Procainamide
Metoclopramide {u} (Compound) binds {v} (Gene) DRD3
Metoclopramide {u} (Compound) palliates {v} (Disease) migraine
Metoclopramide {u} (Compound) is included by {v} (Pharmacologic Class) Dopamine D2 Antagonists
Metoclopramide {u} (Compound) causes {v} (Side Effect) Somnolence
Metoclopramide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dopamine
Metoclopramide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Desvenlafaxine
Metoclopramide {u} may lead to a major life threatening interaction when taken with {v} Paliperidone
Metoclopramide (Compound) resembles Cinchocaine (Compound)
Metoclopramide (Compound) resembles Procaine (Compound)
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Procainamide
Metoclopramide (Compound) binds DRD3 (Gene)
Metoclopramide (Compound) palliates migraine (Disease)
Metoclopramide (Compound) is included by Dopamine D2 Antagonists (Pharmacologic Class)
Metoclopramide (Compound) causes Somnolence (Side Effect)
Metoclopramide may cause a minor interaction that can limit clinical effects when taken with Dopamine
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine
Metoclopramide may lead to a major life threatening interaction when taken with Paliperidone